Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip D Home

Showing results (21-30 of 61) with videos related to

Pageof 7
Sort By:
Diabetes Care|March 15, 2008
Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetesSimon G Ashwell, Clare Bradley, James W Stephens, et al.
Diabetes Research and Clinical Practice|October 15, 2013
The effectiveness and safety of beginning insulin aspart together with basal insulin in people with type 2 diabetes in non-Western nations: results from the A₁chieve observational studyPhilip D Home, Zafar A Latif, Guillermo González-Gálvez, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 31, 2014
Safety, tolerability, and efficacy of insulin aspart in people with type 2 diabetes, as biphasic insulin aspart or with Basal insulin: findings from the multinational, non-interventional a1chieve studyIssam Hajjaji, Siddharth Shah, Yuxiu Li, et al.
Diabetes, Obesity & Metabolism|April 22, 2020
Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trialGeremia B Bolli, Wolfgang Landgraf, Zsolt Bosnyak, et al.
Diabetes Research and Clinical Practice|May 15, 2010
Observational studies: going beyond the boundaries of randomized controlled trialsWenying Yang, Alexey Zilov, Pradana Soewondo, et al.
Pharmacoeconomics|June 28, 2006
A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategiesAdrian Bagust, Marc Evans, Sophie Beale, et al.
Diabetes Research and Clinical Practice|March 31, 2015
Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: The CREDIT studyBeverley Balkau, Françoise Calvi-Gries, Nick Freemantle, et al.
Diabetes Care|April 30, 2002
Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetesAnders Lindholm, Lisbeth B Jensen, Philip D Home, et al.
Cardiovascular Diabetology|June 3, 2009
A study of endothelial function and circulating asymmetric dimethylarginine levels in people with Type 1 diabetes without macrovascular disease or microalbuminuriaLatika Sibal, Sharad C Agarwal, Edzard Schwedhelm, et al.
Annals of Clinical Biochemistry|February 21, 2002
Standardization of glycated haemoglobinSally M Marshall, Philip D Home, Susan E Manley, et al.
Pageof 7

Showing results (21-30 of 61) with videos related to

Sort By:
Pageof 7
Diabetes Care|March 15, 2008
Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetesSimon G Ashwell, Clare Bradley, James W Stephens, et al.
Diabetes Research and Clinical Practice|October 15, 2013
The effectiveness and safety of beginning insulin aspart together with basal insulin in people with type 2 diabetes in non-Western nations: results from the A₁chieve observational studyPhilip D Home, Zafar A Latif, Guillermo González-Gálvez, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 31, 2014
Safety, tolerability, and efficacy of insulin aspart in people with type 2 diabetes, as biphasic insulin aspart or with Basal insulin: findings from the multinational, non-interventional a1chieve studyIssam Hajjaji, Siddharth Shah, Yuxiu Li, et al.
Diabetes, Obesity & Metabolism|April 22, 2020
Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trialGeremia B Bolli, Wolfgang Landgraf, Zsolt Bosnyak, et al.
Diabetes Research and Clinical Practice|May 15, 2010
Observational studies: going beyond the boundaries of randomized controlled trialsWenying Yang, Alexey Zilov, Pradana Soewondo, et al.
Pharmacoeconomics|June 28, 2006
A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategiesAdrian Bagust, Marc Evans, Sophie Beale, et al.
Diabetes Research and Clinical Practice|March 31, 2015
Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: The CREDIT studyBeverley Balkau, Françoise Calvi-Gries, Nick Freemantle, et al.
Diabetes Care|April 30, 2002
Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetesAnders Lindholm, Lisbeth B Jensen, Philip D Home, et al.
Cardiovascular Diabetology|June 3, 2009
A study of endothelial function and circulating asymmetric dimethylarginine levels in people with Type 1 diabetes without macrovascular disease or microalbuminuriaLatika Sibal, Sharad C Agarwal, Edzard Schwedhelm, et al.
Annals of Clinical Biochemistry|February 21, 2002
Standardization of glycated haemoglobinSally M Marshall, Philip D Home, Susan E Manley, et al.
Pageof 7